Search:
Eligible? Enter your email with the company domain to determine your eligibility.

Am I Eligible?

By entering your location and email address, we can determine if your company is eligible to participate in the BIO Business Solutions® cost - savings programs. If your company is eligible you will be directed to a page outlining the benefits available to you.

Not in the US? View programs available in:

Non-Immuno-Oncology and Immuno-Oncology Partnering and Development: What's the Role of Non-IO in an IO World

January 26th, at 11am Pacific/2pm Eastern

Sponsored by ShareVault, Pullan Consulting, Defined Health and BIO

In this live web panel, the panelists will discuss the role of non-immuno-oncology treatments for cancer in a world where immuno-oncology is playing a greater role.  Biotech licensing and pharmaceutical business development consultant Linda Pullan will be joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm. 

Discussion Synopsis

The clinical success of checkpoint inhibitors has made Immuno-Oncology an amazingly "hot" area for pharmaceutical and biotech deal making.  With checkpoint antibodies seen as backbones for combination therapy in cancer, many in Oncology are asking:

What is the role of non-IO in an IO world and can you partner a non-IO opportunity?

•Is there still room for new anticancer agents that are not working in IO models?

•Are drug candidates evaluated with the assumption that everything will eventually be used in combination with IO agents?  Or are there indications or mechanisms for which IO will never be important?  Should I pursue combinations with IO?

•What kinds of mechanisms are attractive in non-IO?  What data and models will big pharma want to see?   Do I need to run experiments with their molecule?  Are there certain tumor types that are particularly attractive?

•Is it too late to try to compete in the crowded space of combination with PD1 antibodies?  What other IO agents are likely to backbones of oncology franchises?

•What will make my non-IO drug candidate compelling for partners and investors?

We will ask these experts from industry and academia the questions and answer your questions as well. 

Moderator:  Linda Pullan, PhD | Pullan Consulting

Panelists:      Jeff Bockman, PhD | Defined Health

                       Peter Sandor, MD, MBA | Astellas Pharma

                       Axel Hoos, MD, PhD | GlaxoSmithKline

                       Eric Haura, MD | H. Lee Moffitt Cancer Center 

 

To join this lively Q&A, register here: http://bit.ly/2iA43C1

 

Jan 18, 2017 | Email | 
TAGS: